Peter G Falkai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8557176/publications.pdf

Version: 2024-02-01

528 papers	24,927 citations	6592 79 h-index	12910 131 g-index
585 all docs	585 docs citations	585 times ranked	24772 citing authors

#	Article	IF	Citations
1	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry, 2017, 174, 216-229.	4.0	685
2	Machine Learning Approaches for Clinical Psychology and Psychiatry. Annual Review of Clinical Psychology, 2018, 14, 91-118.	6.3	520
3	Hippocampal Plasticity in Response to Exercise in Schizophrenia. Archives of General Psychiatry, 2010, 67, 133.	13.8	503
4	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World Journal of Biological Psychiatry, 2012, 13, 318-378.	1.3	498
5	Cell loss in the hippocampus of schizophrenics. European Archives of Psychiatry and Neurological Sciences, 1986, 236, 154-161.	0.9	465
6	EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). European Psychiatry, 2018, 54, 124-144.	0.1	377
7	Accelerated Brain Aging in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders. Schizophrenia Bulletin, 2014, 40, 1140-1153.	2.3	369
8	Fear is only as deep as the mind allows. NeuroImage, 2011, 58, 275-285.	2.1	367
9	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World Journal of Biological Psychiatry, 2013, 14, 2-44.	1.3	343
10	Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Research, 2000, 42, 203-210.	0.8	310
11	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet, The, 2016, 387, 1085-1093.	6.3	306
12	microRNA-34c is a novel target to treat dementias. EMBO Journal, 2011, 30, 4299-4308.	3.5	302
13	Evidence for activation of microglia in patients with psychiatric illnesses. Neuroscience Letters, 1999, 271, 126-128.	1.0	296
14	Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: a systematic review. Journal of Neural Transmission, 2010, 117, 105-122.	1.4	289
15	Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the â€œTwo hit hypothesisâ€• Journal of Psychiatric Research, 1999, 33, 543-548.	1.5	283
16	The role of the human ventral striatum and the medial orbitofrontal cortex in the representation of reward magnitude â€“ An activation likelihood estimation meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing. Neuropsychologia, 2012, 50, 1252-1266.	0.7	281
17	Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression. JAMA Psychiatry, 2018, 75, 1156.	6.0	251
18	Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia. New England Journal of Medicine, 2006, 354, 472-482.	13.9	249

#	Article	IF	Citations
19	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry, 2005, 6, 132-191.	1.3	242
20	The impact of environmental factors in severe psychiatric disorders. Frontiers in Neuroscience, 2014, 8, 19.	1.4	242
21	Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture. PLoS Genetics, 2013, 9, e1003864.	1.5	241
22	Post-mortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics. Schizophrenia Research, 1990, 3, 295-301.	1.1	223
23	Common and distinct neural correlates of emotional processing in Bipolar Disorder and Major Depressive Disorder: A voxel-based meta-analysis of functional magnetic resonance imaging studies. European Neuropsychopharmacology, 2012, 22, 100-113.	0.3	206
24	Schizophrenia as a disorder of disconnectivity. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 150-154.	1.8	197
25	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia. World Journal of Biological Psychiatry, 2006, 7, 5-40.	1.3	194
26	Effects of antipsychotics on brain structure. Current Opinion in Psychiatry, 2006, 19, 145-150.	3.1	185
27	Detecting Neuroimaging Biomarkers for Schizophrenia: A Meta-Analysis of Multivariate Pattern Recognition Studies. Neuropsychopharmacology, 2015, 40, 1742-1751.	2.8	182
28	Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Human Molecular Genetics, 2016, 25, 3383-3394.	1.4	182
29	Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 367-377.	1.8	177
30	Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. Journal of Psychiatric Research, 2010, 44, 1176-1189.	1.5	158
31	Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS ONE, 2013, 8, e65636.	1.1	156
32	The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. American Journal of Psychiatry, 2017, 174, 840-849.	4.0	155
33	Loss of sylvian fissure asymmetry in schizophrenia. Schizophrenia Research, 1992, 7, 23-32.	1.1	148
34	Functional neuroimaging of reward processing and decision-making: A review of aberrant motivational and affective processing in addiction and mood disorders. Brain Research Reviews, 2008, 59, 164-184.	9.1	146
35	Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathologica, 2009, 117, 395-407.	3.9	146
36	Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. Lancet Psychiatry,the, 2016, 3, 935-946.	3.7	144

#	Article	IF	Citations
37	Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behavioural Brain Research, 2011, 224, 15-22.	1.2	140
38	Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons. Psychiatry Research - Neuroimaging, 1998, 82, 1-10.	0.9	137
39	Detecting the Psychosis Prodrome Across High-Risk Populations Using Neuroanatomical Biomarkers. Schizophrenia Bulletin, 2015, 41, 471-482.	2.3	136
40	Disturbed Gyrification of the Prefrontal Region in Male Schizophrenic Patients: A Morphometric Postmortem Study. American Journal of Psychiatry, 2000, 157, 34-39.	4.0	135
41	Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. Brain, 2015, 138, 2059-2073.	3.7	132
42	A Review and New Report of Medial Temporal Lobe Dysfunction as a Vulnerability Indicator for Schizophrenia: A Magnetic Resonance Imaging Morphometric Family Study of the Parahippocampal Gyrus. Schizophrenia Bulletin, 2003, 29, 803-830.	2.3	128
43	Abnormalities of SNARE Mechanism Proteins in Anterior Frontal Cortex in Severe Mental Illness. Cerebral Cortex, 2002, 12, 349-356.	1.6	127
44	Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. Journal of Neural Transmission, 2015, 122, 1055-1068.	1.4	126
45	Advantages and disadvantages of combination treatment with antipsychotics. European Neuropsychopharmacology, 2009, 19, 520-532.	0.3	125
46	Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression. JAMA Psychiatry, 2021, 78, 195.	6.0	125
47	Left Prefrontal High-Frequency Repetitive Transcranial Magnetic Stimulation for the Treatment of Schizophrenia with Predominant Negative Symptoms: A Sham-Controlled, Randomized Multicenter Trial. Biological Psychiatry, 2015, 77, 979-988.	0.7	122
48	Volumes of association thalamic nuclei in schizophrenia: a postmortem study. Schizophrenia Research, 2003, 60, 141-155.	1.1	118
49	Entorhinal cortex pre-alpha cell clusters in schizophrenia: quantitative evidence of a developmental abnormality. Biological Psychiatry, 2000, 47, 937-943.	0.7	117
50	Cross-Disorder Genome-Wide Analyses Suggest a Complex Genetic Relationship Between Tourette's Syndrome and OCD. American Journal of Psychiatry, 2015, 172, 82-93.	4.0	117
51	Detecting Neuroimaging Biomarkers for Depression: A Meta-analysis of Multivariate Pattern Recognition Studies. Biological Psychiatry, 2017, 82, 330-338.	0.7	116
52	The Longitudinal Course of Schizophrenia Across the Lifespan. Harvard Review of Psychiatry, 2016, 24, 118-128.	0.9	112
53	Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior, 2003, 4, 674-679.	0.9	111
54	Copy Number Variation in Obsessive-Compulsive Disorder and Tourette Syndrome: A Cross-Disorder Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 910-919.	0.3	111

#	Article	IF	Citations
55	Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. Acta Neuropathologica, 2012, 124, 893-903.	3.9	110
56	Prefrontal Transcranial Direct Current Stimulation for Treatment of Schizophrenia With Predominant Negative Symptoms: A Double-Blind, Sham-Controlled Proof-of-Concept Study. Schizophrenia Bulletin, 2016, 42, 1253-1261.	2.3	110
57	Disturbed functional connectivity within brain networks subserving domain-specific subcomponents of working memory in schizophrenia: Relation to performance and clinical symptoms. Journal of Psychiatric Research, 2010, 44, 364-372.	1.5	109
58	Borderline personality disorder: A dysregulation of the endogenous opioid system?. Psychological Review, 2010, 117, 623-636.	2.7	108
59	Hippocampal Complexin Proteins and Cognitive Dysfunction in Schizophrenia. Archives of General Psychiatry, 2005, 62, 263.	13.8	107
60	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World Journal of Biological Psychiatry, 2015, 16, 142-170.	1.3	106
61	Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disorders, 2005, 7, 449-455.	1.1	105
62	Motor Cortical Excitability Assessed by Transcranial Magnetic Stimulation in Psychiatric Disorders: A Systematic Review. Brain Stimulation, 2014, 7, 158-169.	0.7	105
63	Right Frontal Hypergyria Differentiation in Affected and Unaffected Siblings From Families Multiply Affected With Schizophrenia: A Morphometric MRI Study. American Journal of Psychiatry, 2001, 158, 494-496.	4.0	104
64	Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder. JAMA Psychiatry, 2018, 75, 65-74.	6.0	102
65	Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 497-507.	3.9	101
66	Increased prevalence of the cavum septum pellucidum in magnetic resonance scans and post-mortem brains of schizophrenic patients. Psychiatry Research - Neuroimaging, 1992, 45, 1-13.	0.9	99
67	Immunohistochemical Evidence for Impaired Neuregulin-1 Signaling in the Prefrontal Cortex in Schizophrenia and in Unipolar Depression. Annals of the New York Academy of Sciences, 2007, 1096, 147-156.	1.8	99
68	Impaired long-term depression in schizophrenia: AÂcathodal tDCS pilot study. Brain Stimulation, 2012, 5, 475-483.	0.7	99
69	Childhood Trauma in Schizophrenia: Current Findings and Research Perspectives. Frontiers in Neuroscience, 2019, 13, 274.	1.4	99
70	Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. British Journal of Psychiatry, 2005, 186, 410-416.	1.7	97
71	Genetic Load on Amygdala Hypofunction During Sadness in Nonaffected Brothers of Schizophrenia Patients. American Journal of Psychiatry, 2004, 161, 1806-1813.	4.0	95
72	Amplitude reduction of the mismatch negativity in first-degree relatives of patients with schizophrenia. Neuroscience Letters, 2001, 309, 185-188.	1.0	94

#	Article	IF	Citations
73	Vagus nerve stimulation in psychiatry: a systematic review of the available evidence. Journal of Neural Transmission, 2017, 124, 145-158.	1.4	94
74	Essential Functions of the Human Self Model Are Implemented in the Prefrontal Cortex. Consciousness and Cognition, 1999, 8, 343-363.	0.8	92
75	Intake of copper has no effect on cognition in patients with mild Alzheimerâ€™s disease: a pilot phase 2 clinical trial. Journal of Neural Transmission, 2008, 115, 1181-1187.	1.4	92
76	The role of the cerebellum in schizophrenia: from cognition to molecular pathways. Clinics, 2011, 66, 71-77.	0.6	91
77	The effects of physical exercise in schizophrenia and affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 451-467.	1.8	90
78	Î±-Synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease Î²-amyloid plaque cores. Neuroscience Letters, 1999, 266, 213-216.	1.0	88
79	Modification of Cognitive Performance in Schizophrenia by Complexin 2 Gene Polymorphisms. Archives of General Psychiatry, 2010, 67, 879.	13.8	86
80	Results of the COVID-19 mental health international for the general population (COMET-G) study. European Neuropsychopharmacology, 2022, 54, 21-40.	0.3	84
81	Familiality of Obsessive-Compulsive Disorder in Nonclinical and Clinical Subjects. American Journal of Psychiatry, 2006, 163, 1986-1992.	4.0	83
82	Effects of Endurance Training Combined With Cognitive Remediation on Everyday Functioning, Symptoms, and Cognition in Multiepisode Schizophrenia Patients. Schizophrenia Bulletin, 2015, 41, 847-858.	2.3	83
83	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1186-1200.	3.7	83
84	Proteome analysis of schizophrenia brain tissue. World Journal of Biological Psychiatry, 2010, 11, 110-120.	1.3	82
85	Aberrant Functional Whole-Brain Network Architecture in Patients With Schizophrenia: A Meta-analysis. Schizophrenia Bulletin, 2016, 42, S13-S21.	2.3	80
86	Functional brain abnormalities in psychiatric disorders: Neural mechanisms to detect and resolve cognitive conflict and interference. Brain Research Reviews, 2008, 59, 96-124.	9.1	79
87	Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. Journal of Alzheimer's Disease, 2005, 8, 23-27.	1.2	78
88	Classifying Schizophrenia Using Multimodal Multivariate Pattern Recognition Analysis: Evaluating the Impact of Individual Clinical Profiles on the Neurodiagnostic Performance. Schizophrenia Bulletin, 2016, 42, S110-S117.	2.3	78
89	Brain Subtyping Enhances The Neuroanatomical Discrimination of Schizophrenia. Schizophrenia Bulletin, 2018, 44, 1060-1069.	2.3	78
90	Correlation between amygdala volume and age in bipolar disorder â€” A systematic review and meta-analysis of structural MRI studies. Psychiatry Research - Neuroimaging, 2010, 182, 1-8.	0.9	76

#	Article	IF	Citations
91	Maintenance Treatment With Risperidone or Low-Dose Haloperidol in First-Episode Schizophrenia. Journal of Clinical Psychiatry, 2007, 68, 1763-1774.	1.1	76
92	HDAC1 links early life stress to schizophrenia-like phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4686-E4694.	3.3	75
93	Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophrenia Research, 2006, 87, 81-88.	1.1	74
94	Health-Related Quality of Life in Hereditary Hemorrhagic Telangiectasia. Otolaryngology - Head and Neck Surgery, 2007, 136, 726-733.	1.1	74
95	In vivo morphometry of planum temporale asymmetry in first-episode schizophrenia. Schizophrenia Research, 1994, 12, 9-18.	1.1	73
96	Effects of social exclusion on emotions and oxytocin and cortisol levels in patients with chronic depression. Journal of Psychiatric Research, 2015, 60, 170-177.	1.5	73
97	Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. Journal of Psychiatric Research, 2010, 44, 989-991.	1.5	72
98	Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level. JAMA Psychiatry, 2021, 78, 667.	6.0	72
99	Cognitive Effects of High-Frequency rTMS in Schizophrenia Patients With Predominant Negative Symptoms: Results From a Multicenter Randomized Sham-Controlled Trial. Schizophrenia Bulletin, 2016, 42, 608-618.	2.3	71
100	The dichotomy of schizophrenia and affective disorders in extended pedigrees. Schizophrenia Research, 2002, 57, 259-266.	1.1	70
101	Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 601-612.	1.8	70
102	Muscle and Timing-specific Functional Connectivity between the Dorsolateral Prefrontal Cortex and the Primary Motor Cortex. Journal of Cognitive Neuroscience, 2013, 25, 558-570.	1.1	69
103	Increased serum S100B in elderly, chronic schizophrenic patients: Negative correlation with deficit symptoms. Schizophrenia Research, 2005, 80, 305-313.	1.1	68
104	Neural substrates of olfactory processing in schizophrenia patients and their healthy relatives. Psychiatry Research - Neuroimaging, 2007, 155, 103-112.	0.9	68
105	Decreased Oligodendrocyte and Neuron Number in Anterior Hippocampal Areas and the Entire Hippocampus in Schizophrenia: A Stereological Postmortem Study. Schizophrenia Bulletin, 2016, 42, S4-S12.	2.3	68
106	Bidirectional variability in motor cortex excitability modulation following 1ÂmA transcranial direct current stimulation in healthy participants. Physiological Reports, 2016, 4, e12884.	0.7	66
107	Quantitative study of gliosis in schizophrenia and huntington's chorea. Biological Psychiatry, 1988, 24, 697-700.	0.7	64
108	Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World Journal of Biological Psychiatry, 2009, 10, 127-155.	1.3	64

#	Article	IF	Citations
109	The effect of long-term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controlsâ€"A randomized placebo-controlled, double-blind fMRI study. Behavioural Brain Research, 2013, 237, 300-307.	1.2	64
110	Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules. NPJ Schizophrenia, 2015, 1, 15034.	2.0	64
111	Effects of endurance training on brain structures in chronic schizophrenia patients and healthy controls. Schizophrenia Research, 2016, 173, 182-191.	1.1	64
112	Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. Neuroscience Letters, 2000, 289, 147-151.	1.0	63
113	A CAG repeat polymorphism of KCNN3 predicts SK3 channel function and cognitive performance in schizophrenia. EMBO Molecular Medicine, 2011, 3, 309-319.	3.3	63
114	Hippocampal deformities in the unaffected siblings of schizophrenia subjects. Biological Psychiatry, 2003, 54, 1234-1240.	0.7	62
115	Cognitive impairment of executive function as a core symptom of schizophrenia. World Journal of Biological Psychiatry, 2009, 10, 442-451.	1.3	62
116	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia â€“ a short version for primary care. International Journal of Psychiatry in Clinical Practice, 2017, 21, 82-90.	1.2	61
117	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	4.1	61
118	Efficacy and safety of clozapine in psychotic disordersâ€"a systematic quantitative meta-review. Translational Psychiatry, 2021, 11, 487.	2.4	61
119	Neural expression profile of Î±-synuclein in developing human cortex. NeuroReport, 1999, 10, 2799-2803.	0.6	60
120	Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. World Journal of Biological Psychiatry, 2011, 12, 201-215.	1.3	60
121	Disturbed frontal gyrification within families affected with schizophrenia. Journal of Psychiatric Research, 2007, 41, 805-813.	1.5	59
122	Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 589-600.	1.8	59
123	Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 803-818.	1.8	59
124	Increased serum interleukin-I? and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatric Disease and Treatment, 2005, 1, 171-177.	1.0	59
125	Harm avoidance in subjects with obsessive-compulsive disorder and their families. Journal of Affective Disorders, 2008, 107, 265-269.	2.0	58
126	The effect of aerobic exercise on cortical architecture in patients with chronic schizophrenia: a randomized controlled MRI study. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 469-473.	1.8	58

#	Article	IF	Citations
127	Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study. Schizophrenia Research, 2016, 177, 59-66.	1.1	58
128	Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia â€"Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophrenia Bulletin, 2020, 46, 1459-1470.	2.3	58
129	Pathological amygdala activation during working memory performance: Evidence for a pathophysiological trait marker in bipolar affective disorder. Human Brain Mapping, 2010, 31, 115-125.	1.9	57
130	Predicting Response to Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia Using Structural Magnetic Resonance Imaging: A Multisite Machine Learning Analysis. Schizophrenia Bulletin, 2018, 44, 1021-1034.	2.3	57
131	Effects of Aerobic Exercise on Metabolic Syndrome, Cardiorespiratory Fitness, and Symptoms in Schizophrenia Include Decreased Mortality. Frontiers in Psychiatry, 2018, 9, 690.	1.3	57
132	Disturbed Anterior Prefrontal Control of the Mesolimbic Reward System and Increased Impulsivity in Bipolar Disorder. Neuropsychopharmacology, 2014, 39, 1914-1923.	2.8	56
133	No change to grey and white matter volumes in bipolar I disorder patients. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 345-349.	1.8	54
134	A Novel Mechanism and Treatment Target for Presynaptic Abnormalities in Specific Striatal Regions in Schizophrenia. Neuropsychopharmacology, 2010, 35, 1226-1238.	2.8	54
135	Articulatory rehearsal in verbal working memory: A possible neurocognitive endophenotype that differentiates between schizophrenia and schizoaffective disorder. Neuroscience Letters, 2006, 405, 24-28.	1.0	53
136	The cross-sectional GRAS sample: A comprehensive phenotypical data collection of schizophrenic patients. BMC Psychiatry, 2010, 10, 91.	1.1	53
137	Impulsive personality and the ability to resist immediate reward: An fMRI study examining interindividual differences in the neural mechanisms underlying selfâ€control. Human Brain Mapping, 2012, 33, 2768-2784.	1.9	53
138	Effect of copper intake on CSF parameters in patients with mild Alzheimerâ€™s disease: a pilot phaseÂ2 clinical trial. Journal of Neural Transmission, 2008, 115, 1651-1659.	1.4	52
139	Clozapine augmentation strategies â€“ a systematic meta-review of available evidence. Treatment options for clozapine resistance. Journal of Psychopharmacology, 2019, 33, 423-435.	2.0	52
140	Oral Î”9-Tetrahydrocannabinol Improved Refractory Gilles de la Tourette Syndrome in an Adolescent by Increasing Intracortical Inhibition. Journal of Clinical Psychopharmacology, 2010, 30, 190-192.	0.7	51
141	Lower Oxytocin Plasma Levels in Borderline Patients with Unresolved Attachment Representations. Frontiers in Human Neuroscience, 2016, 10, 125.	1.0	51
142	The ventral lateral posterior nucleus of the thalamus in schizophrenia: a post-mortem study. Psychiatry Research - Neuroimaging, 2002, 114, 1-9.	0.9	50
143	Deficient Inhibitory Cortical Networks in Antipsychotic-Naive Subjects at Risk of Developing First-Episode Psychosis and First-Episode Schizophrenia Patients: A Cross-Sectional Study. Biological Psychiatry, 2012, 72, 744-751.	0.7	50
144	CACNA1C genotype explains interindividual differences in amygdala volume among patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 93-102.	1.8	50

#	Article	IF	Citations
145	Prediction of outcome in the psychosis prodrome using neuroanatomical pattern classification. Schizophrenia Research, 2016, 173, 159-165.	1.1	50
146	Objective Quantification of the Tinnitus Decompensation by Synchronization Measures of Auditory Evoked Single Sweeps. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2008, 16, 74-81.	2.7	49
147	Oligodendrocytes as A New Therapeutic Target in Schizophrenia: From Histopathological Findings to Neuron-Oligodendrocyte Interaction. Cells, 2019, 8, 1496.	1.8	49
148	Alexithymia in Obsessive-Compulsive Disorder â€“ Results from a Family Study. Psychotherapy and Psychosomatics, 2006, 75, 312-318.	4.0	48
149	Autoimmune encephalitis with psychosis: Warning signs, step-by-step diagnostics and treatment. World Journal of Biological Psychiatry, 2020, 21, 241-254.	1.3	48
150	Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World Journal of Biological Psychiatry, 2010, 11, 719-728.	1.3	47
151	A functional neuroimaging study assessing gender differences in the neural mechanisms underlying the ability to resist impulsive desires. Brain Research, 2012, 1473, 63-77.	1.1	47
152	Characterization of SLITRK1 Variation in Obsessive-Compulsive Disorder. PLoS ONE, 2013, 8, e70376.	1.1	47
153	A longitudinal approach to biological psychiatric research: The PsyCourse study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 89-102.	1.1	47
154	Developmental abnormalities of the hippocampus in First-Episode schizophrenia. Biological Psychiatry, 2003, 53, 555-561.	0.7	45
155	Antisaccade performance in patients with obsessiveâ€“compulsive disorder and unaffected relatives: further evidence for impaired response inhibition as a candidate endophenotype. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 625-634.	1.8	45
156	Formin 2 links neuropsychiatric phenotypes at young age to an increased risk for dementia. EMBO Journal, 2017, 36, 2815-2828.	3.5	45
157	Mental health in refugees and asylum seekers (MEHIRA): study design and methodology of a prospective multicentre randomized controlled trail investigating the effects of a stepped and collaborative care model. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 95-106.	1.8	45
158	Neuregulin-1 haplotype HAPICE is associated with lower hippocampal volumes in schizophrenic patients and in non-affected family members. Journal of Psychiatric Research, 2008, 43, 1-6.	1.5	44
159	Prefrontal transcranial direct current stimulation (tDCS) as treatment for major depression: study design and methodology of a multicenter triple blind randomized placebo controlled trial (DepressionDC). European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 751-766.	1.8	44
160	Synaptosomal Proteome of the Orbitofrontal Cortex from Schizophrenia Patients Using Quantitative Label-Free and iTRAQ-Based Shotgun Proteomics. Journal of Proteome Research, 2017, 16, 4481-4494.	1.8	44
161	Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. Molecular Psychiatry, 2021, 26, 2457-2470.	4.1	44
162	Effects of abstinence on brain morphology in alcoholism. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 143-150.	1.8	43

#	Article	IF	Citations
163	Genetic polymorphisms of 5-HTT and DAT but not COMT differentially affect verbal and visuospatial working memory functioning. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 667-676.	1.8	43
164	Social Exclusion Leads to Divergent Changes of Oxytocin Levels in Borderline Patients and Healthy Subjects. Psychotherapy and Psychosomatics, 2014, 83, 252-254.	4.0	43
165	Compensatory hyperactivations as markers of latent working memory dysfunctions in patients with obsessive-compulsive disorder: an fMRI study. Journal of Psychiatry and Neuroscience, 2008, 33, 209-15.	1.4	43
166	Borna Disease Virus in Human Brains with a Rare Form of Hippocampal Degeneration but Not in Brains of Patients with Common Neuropsychiatric Disorders. Journal of Infectious Diseases, 1999, 180, 1695-1699.	1.9	41
167	Early onset of obsessive-compulsive disorder and associated comorbidity. Depression and Anxiety, 2009, 26, 1012-1017.	2.0	41
168	Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 101-111.	1.8	41
169	Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 23-31.	1.8	41
170	Aerobic exercise and its effects on cognition in schizophrenia. Current Opinion in Psychiatry, 2017, 30, 171-175.	3.1	41
171	Reduction of the Internal Capsule in Families Affected with Schizophrenia. Biological Psychiatry, 2008, 63, 65-71.	0.7	40
172	Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. World Journal of Biological Psychiatry, 2010, 11, 243-250.	1.3	40
173	Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 3-13.	1.8	40
174	Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anatomy and Embryology, 2005, 210, 519-523.	1.5	39
175	Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 203-210.	1.8	39
176	An Investigation of Psychosis Subgroups With Prognostic Validation and Exploration of Genetic Underpinnings. JAMA Psychiatry, 2020, 77, 523.	6.0	39
177	Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 567-575.	1.8	38
178	Cortical sulcal enlargement in catatonic schizophrenia: a planimetric CT study. Psychiatry Research - Neuroimaging, 1999, 91, 45-54.	0.9	37
179	Automated image analysis of disturbed cytoarchitecture in Brodmann area 10 in schizophrenia. Schizophrenia Research, 2003, 62, 133-140.	1.1	37
180	Reduced prefrontal gyrification in obsessiveâ€“compulsive disorder. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 455-464.	1.8	37

#	Article	IF	Citations
181	The Diagnosis and Treatment of Bipolar Disorder. Deutsches Ärzteblatt International, 2013, 110, 92-100.	0.6	37
182	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology. World Journal of Biological Psychiatry, 2015, 16, 280-290.	1.3	37
183	Disturbed corticoâ€“amygdalar functional connectivity as pathophysiological correlate of working memory deficits in bipolar affective disorder. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 303-311.	1.8	37
184	Oligodendrocyte and Interneuron Density in Hippocampal Subfields in Schizophrenia and Association of Oligodendrocyte Number with Cognitive Deficits. Frontiers in Cellular Neuroscience, 2016, 10, 78.	1.8	37
185	Absence of cerebrospinal fluid antineuronal antibodies in schizophrenia spectrum disorders. British Journal of Psychiatry, 2018, 212, 318-320.	1.7	37
186	Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2000, 24, 881-888.	2.5	36
187	Comorbid substance abuse and brain morphology in recent-onset psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 28-36.	1.8	36
188	Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse. Psychopharmacology, 2010, 208, 353-363.	1.5	36
189	Decreased Reelin Expression in the Left Prefrontal Cortex (BA9) in Chronic Schizophrenia Patients. Neuropsychobiology, 2012, 66, 57-62.	0.9	36
190	Hippocampal integrity and neurocognition in first-episode schizophrenia: A multidimensional study. World Journal of Biological Psychiatry, 2014, 15, 188-199.	1.3	36
191	Brain morphology assessed by computed tomography in patients with geriatric depression, patients with degenerative dementia, and normal control subjects. Psychiatry Research - Neuroimaging, 1995, 61, 103-111.	0.9	35
192	Reduced tyrosine kinase receptor C mRNA levels in the frontal cortex of patients with schizophrenia. Neuroscience Letters, 1998, 257, 65-68.	1.0	35
193	Neurobiological effects of aerobic exercise, with a focus on patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 499-515.	1.8	35
194	Traces of Trauma: A Multivariate Pattern Analysis of Childhood Trauma, Brain Structure, and Clinical Phenotypes. Biological Psychiatry, 2020, 88, 829-842.	0.7	35
195	The hippocampus in families with schizophrenia in relation to obstetric complications. Schizophrenia Research, 2008, 104, 71-78.	1.1	34
196	Obsessive-Compulsive Disorder and Posttraumatic Stress Disorder. Psychopathology, 2008, 41, 129-134.	1.1	34
197	Internal capsule size associated with outcome in first-episode schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 278-283.	1.8	34
198	Loss of Munc18-1 long splice variant in GABAergic terminals is associated with cognitive decline and increased risk of dementia in a community sample. Molecular Neurodegeneration, 2015, 10, 65.	4.4	34

#	Article	IF	Citations
199	Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia. Schizophrenia Research, 2016, 170, 168-176.	1.1	34
200	Spironolactone is an antagonist of <scp>NRG</scp> 1â€•<scp>ERBB</scp> 4 signaling and schizophreniaâ€relevant endophenotypes in mice. EMBO Molecular Medicine, 2017, 9, 1448-1462.	3.3	34
201	Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project. International Journal of Neuropsychopharmacology, 2018, 21, 814-821.	1.0	34
202	Effects of stimulant drug use on the dopaminergic system: A systematic review and meta-analysis of in vivo neuroimaging studies. European Psychiatry, 2019, 59, 15-24.	0.1	34
203	DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 209-215.	1.8	33
204	The power of imagination â€" How anticipatory mental imagery alters perceptual processing of fearful facial expressions. NeuroImage, 2011, 54, 1703-1714.	2.1	33
205	Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophrenia Research, 2014, 152, 478-486.	1.1	33
206	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. World Journal of Biological Psychiatry, 2017, 18, 330-356.	1.3	33
207	A Pattern of Cognitive Deficits Stratified for Genetic and Environmental Risk Reliably Classifies Patients With Schizophrenia From Healthy Control Subjects. Biological Psychiatry, 2020, 87, 697-707.	0.7	33
208	The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains. Molecular Neuropsychiatry, 2017, 3, 37-52.	3.0	32
209	Accuracy of diagnostic classification and clinical utility assessment of ICD-11 compared to ICD-10 in 10 mental disorders: findings from a web-based field study. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 281-289.	1.8	32
210	Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort. Biological Psychiatry, 2021, 90, 632-642.	0.7	32
211	Influence of genetic loading, obstetric complications and premorbid adjustment on brain morphology in schizophrenia:. European Archives of Psychiatry and Clinical Neuroscience, 2003, 253, 92-99.	1.8	31
212	Increased d-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. Journal of Neural Transmission, 2009, 116, 1657-1665.	1.4	31
213	Evidence for specific cognitive deficits in visual information processing in patients with OCD compared to patients with unipolar depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 984-991.	2.5	31
214	Structural synaptic elements are differentially regulated in superior temporal cortex of schizophrenia patients. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 565-577.	1.8	31
215	Studying and modulating schizophrenia-associated dysfunctions of oligodendrocytes with patient-specific cell systems. NPJ Schizophrenia, 2018, 4, 23.	2.0	31
216	Improving working memory in schizophrenia: Effects of 1â€¯mA and 2â€¯mA transcranial direct current stimulation to the left DLPFC. Schizophrenia Research, 2018, 202, 203-209.	1.1	31

#	Article	IF	Citations
217	Forty years of structural brain imaging in mental disorders: is it clinically useful or not?. Dialogues in Clinical Neuroscience, 2018, 20, 179-186.	1.8	31
218	Association between myelin basic protein expression and left entorhinal cortex pre-alpha cell layer disorganization in schizophrenia. Brain Research, 2009, 1301, 126-134.	1.1	30
219	Acute treatment with cannabinoid receptor agonist WIN55212.2 improves prepulse inhibition in psychosocially stressed mice. Behavioural Brain Research, 2011, 218, 280-287.	1.2	30
220	Abnormal bihemispheric responses in schizophrenia patients following cathodal transcranial direct stimulation. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 415-423.	1.8	30
221	Transcranial random noise stimulation for the treatment of negative symptoms in schizophrenia. Schizophrenia Research, 2013, 146, 372-373.	1.1	30
222	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics. World Journal of Biological Psychiatry, 2016, 17, 406-428.	1.3	30
223	A new role for oligodendrocytes and myelination in schizophrenia and affective disorders?. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 371-372.	1.8	29
224	A microRNA signature that correlates with cognition and is a target against cognitive decline. EMBO Molecular Medicine, 2021, 13, e13659.	3.3	29
225	5-HTTLPR genotype influences amygdala volume. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 212-217.	1.8	28
226	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. Frontiers in Psychiatry, 2018, 9, 207.	1.3	28
227	Characteristics and definitions of ultra-treatment-resistant schizophrenia â€“ A systematic review and meta-analysis. Schizophrenia Research, 2021, 228, 218-226.	1.1	28
228	MRI of the brainstem in patients with major depression, bipolar affective disorder and normal controls. Psychiatry Research - Neuroimaging, 2004, 131, 269-276.	0.9	27
229	The orbitofrontal cortex and its role in the assignment of behavioural significance. Neuropsychologia, 2011, 49, 984-991.	0.7	27
230	Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. Scientific Reports, 2017, 7, 9529.	1.6	27
231	Frontotemporal dysregulation of the SNARE protein interactome is associated with faster cognitive decline in old age. Neurobiology of Disease, 2018, 114, 31-44.	2.1	27
232	Brain mechanisms associated with background monitoring of the environment for potentially significant sensory events. Brain and Cognition, 2009, 69, 559-564.	0.8	26
233	Patients with schizophrenia show deficits of working memory maintenance components in circuit-specific tasks. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 519-525.	1.8	26
234	New lexicon and criteria for the diagnosis of Alzheimer's disease. Lancet Neurology, The, 2011, 10, 298-299.	4.9	26

#	Article	IF	Citations
235	Prospective acceptance of distinct mobile mental health features in psychiatric patients and mental health professionals. Journal of Psychiatric Research, 2019, 109, 126-132.	1.5	26
236	Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies. Neuropsychopharmacology, 2019, 44, 660-667.	2.8	26
237	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. World Journal of Biological Psychiatry, 2019, 20, 2-16.	1.3	26
238	Multivariate classification of schizophrenia and its familial risk based on load-dependent attentional control brain functional connectivity. Neuropsychopharmacology, 2020, 45, 613-621.	2.8	26
239	Compartmental volumetry of the superior temporal gyrus reveals sex differences in schizophreniaâ€"a post-mortem study. Schizophrenia Research, 1998, 31, 83-87.	1.1	25
240	Episode-Specific Differential Gene Expression of Peripheral Blood Mononuclear Cells in Rapid Cycling Supports Novel Treatment Approaches. Molecular Medicine, 2008, 14, 546-552.	1.9	25
241	Joint crisis plans and psychiatric advance directives in German psychiatric practice: TableÂ1. Journal of Medical Ethics, 2014, 40, 343-345.	1.0	25
242	BDNF-Val66Met-Polymorphism Impact on Cortical Plasticity in Schizophrenia Patients: A Proof-of-Concept Study. International Journal of Neuropsychopharmacology, 2015, 18, .	1.0	25
243	Stereological investigation of the posterior hippocampus in affective disorders. Journal of Neural Transmission, 2015, 122, 1019-1033.	1.4	25
244	First results of a refeeding program in a psychiatric intensive care unit for patients with extreme anorexia nervosa. BMC Psychiatry, 2015, 15, 57.	1.1	25
245	Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients. Translational Psychiatry, 2021, 11, 606.	2.4	25
246	Differential expression of HINT1 in schizophrenia brain tissue. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 167-172.	1.8	24
247	Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 155-168.	1.8	24
248	The human oligodendrocyte proteome. Proteomics, 2013, 13, 3548-3553.	1.3	24
249	The genetic relationship between educational attainment and cognitive performance in major psychiatric disorders. Translational Psychiatry, 2019, 9, 210.	2.4	24
250	Dysregulation of a specific immune-related network of genes biologically defines a subset of schizophrenia. Translational Psychiatry, 2019, 9, 156.	2.4	24
251	The Role of Self-Esteem in Depression: A Longitudinal Study. Behavioural and Cognitive Psychotherapy, 2019, 47, 244-250.	0.9	24
252	The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: A randomized controlled trial. Drug and Alcohol Dependence, 2011, 118, 417-422.	1.6	23

#	Article	IF	Citations
253	Posttraumatic stress disorder (PTSD) in the German Armed Forces: a retrospective study in inpatients of a German army hospital. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 459-467.	1.8	23
254	Impaired Motor Cortex Responses in Non-Psychotic First-Degree Relatives of Schizophrenia Patients: A Cathodal tDCS Pilot Study. Brain Stimulation, 2013, 6, 821-829.	0.7	23
255	5-HT3 receptor influences the washing phenotype and visual organization in obsessive-compulsive disorder supporting 5-HT3 receptor antagonists as novel treatment option. European Neuropsychopharmacology, 2014, 24, 86-94.	0.3	23
256	Sex Matters: A Multivariate Pattern Analysis of Sex- and Gender-Related Neuroanatomical Differences in Cis- and Transgender Individuals Using Structural Magnetic Resonance Imaging. Cerebral Cortex, 2020, 30, 1345-1356.	1.6	23
257	Compulsory admissions of patients with mental disorders: State of the art on ethical and legislative aspects in 40 European countries. European Psychiatry, 2020, 63, e82.	0.1	23
258	Genome-wide association study of pediatric obsessive-compulsive traits: shared genetic risk between traits and disorder. Translational Psychiatry, 2021, 11, 91.	2.4	23
259	Schizophrenia. Deutsches Ärzteblatt International, 2020, 117, 412-419.	0.6	23
260	The temporal lobes, reversed asymmetry and the genetics of schizophrenia. NeuroReport, 1995, 7, 221-224.	0.6	22
261	Gene expression and neuronal activity in schizophrenia: a study of polyadenylated mRNA in the hippocampal formation and cerebral cortex. Schizophrenia Research, 1997, 26, 93-102.	1.1	22
262	Cerebrospinal Fluid Neurochemical Phenotypes in Vascular Dementias: Original Data and Mini-Review. Dementia and Geriatric Cognitive Disorders, 2008, 25, 256-265.	0.7	22
263	Cortical neurochemistry in euthymic patients with bipolar I disorder. World Journal of Biological Psychiatry, 2009, 10, 285-294.	1.3	22
264	Smoking Restores Impaired LTD-Like Plasticity in Schizophrenia: a Transcranial Direct Current Stimulation Study. Neuropsychopharmacology, 2015, 40, 822-830.	2.8	22
265	Endurance training in patients with schizophrenia and healthy controls: differences and similarities. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 461-473.	1.8	22
266	Differential proteome and phosphoproteome may impact cell signaling in the corpus callosum of schizophrenia patients. Schizophrenia Research, 2016, 177, 70-77.	1.1	22
267	The reliability and clinical utility of ICD-11 schizoaffective disorder: A field trial. Schizophrenia Research, 2019, 208, 235-241.	1.1	22
268	The temporal lobe in schizophrenia from uni- and multiply affected families. Neuroscience Letters, 2002, 325, 25-28.	1.0	21
269	Shotgun mass spectrometry analysis of the human thalamus proteome. Journal of Separation Science, 2009, 32, 1231-1236.	1.3	21
270	Insertion/deletion polymorphism in the gene for angiotensin converting enzyme (ACE) in panic disorder: A gender-specific effect?. World Journal of Biological Psychiatry, 2010, 11, 66-70.	1.3	21

#	Article	IF	Citations
271	A systematic experimental neuropsychological investigation of the functional integrity of working memory circuits in major depression. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 179-184.	1.8	21
272	A systematic review of trials investigating strength training in schizophrenia spectrum disorders. Schizophrenia Research, 2018, 192, 64-68.	1.1	21
273	The need to develop personalized interventions to improve cognition in schizophrenia. World Psychiatry, 2019, 18, 170-170.	4.8	21
274	Quantitative Subcellular Proteomics of the Orbitofrontal Cortex of Schizophrenia Patients. Journal of Proteome Research, 2019, 18, 4240-4253.	1.8	21
275	Effect of aerobic exercise combined with cognitive remediation on cortical thickness and prediction of social adaptation in patients with schizophrenia. Schizophrenia Research, 2020, 216, 397-407.	1.1	21
276	rTMS and tDCS for the treatment of catatonia: A systematic review. Schizophrenia Research, 2020, 222, 73-78.	1.1	21
277	Clinical patterns differentially predict response to transcranial direct current stimulation (tDCS) and escitalopram in major depression: A machine learning analysis of the ELECT-TDCS study. Journal of Affective Disorders, 2020, 265, 460-467.	2.0	21
278	Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 35-39.	1.8	20
279	Is Brain Banking of Psychiatric Cases Valuable for Neurobiological Research?. Clinics, 2008, 63, 255-266.	0.6	20
280	Impairments in motor-cortical inhibitory networks across recent-onset and chronic schizophrenia: A cross-sectional TMS Study. Behavioural Brain Research, 2014, 264, 17-25.	1.2	20
281	Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. Bipolar Disorders, 2019, 21, 68-75.	1.1	20
282	Characterisation of age and polarity at onset in bipolar disorder. British Journal of Psychiatry, 2021, 219, 659-669.	1.7	20
283	Planum temporale asymmetry to the right hemisphere in first-episode schizophrenia. Psychiatry Research - Neuroimaging, 2011, 193, 56-59.	0.9	19
284	Increased cell proliferation in the rat anterior cingulate cortex following neonatal hypoxia: relevance to schizophrenia. Journal of Neural Transmission, 2013, 120, 187-195.	1.4	19
285	Do Manual and Voxel-Based Morphometry Measure the Same? A Proof of Concept Study. Frontiers in Psychiatry, 2014, 5, 39.	1.3	19
286	A Randomized Controlled Trial of Group Coping-Oriented Therapy vs Supportive Therapy in Schizophrenia: Results of a 2-Year Follow-up. Schizophrenia Bulletin, 2016, 42, S71-S80.	2.3	19
287	Efficacy of high-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with treatment-resistant negative symptoms treated with clozapine. Schizophrenia Research, 2019, 208, 370-376.	1.1	19
288	Reconceptualising treatment-resistant depression as difficult-to-treat depression. Lancet Psychiatry,the, 2021, 8, 14-15.	3.7	19

#	Article	IF	Citations
289	Brief Report: Specificity of Interpersonal Synchrony Deficits to Autism Spectrum Disorder and Its Potential for Digitally Assisted Diagnostics. Journal of Autism and Developmental Disorders, 2022, 52, 3718-3726.	1.7	19
290	Automated image analysis of disturbed cytoarchitecture in Brodmann area 10 in schizophrenia: A post-mortem study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2000, 24, 1093-1104.	2.5	18
291	Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. Experimental Gerontology, 2006, 41, 220-224.	1.2	18
292	Dynamic interactions between neural systems underlying different components of verbal working memory. Journal of Neural Transmission, 2007, 114, 1047-1050.	1.4	18
293	Prefrontal cortex gyrification index in twins: an MRI study. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 459-465.	1.8	18
294	S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 311-316.	1.8	18
295	Depression in Somatic Disorders: Is There a Beneficial Effect of Exercise?. Frontiers in Psychiatry, 2019, 10, 141.	1.3	18
296	Diagnosis-specific effect of familial loading on verbal working memory in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 309-315.	1.8	17
297	The â€œDGPPN-Cohortâ€: a national collaboration initiative by the German Association for Psychiatry and Psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 695-701.	1.8	17
298	Functional outcome in major psychiatric disorders and associated clinical and psychosocial variables: A potential cross-diagnostic phenotype for further genetic investigations?. World Journal of Biological Psychiatry, 2015, 16, 237-248.	1.3	17
299	Quantitative mass spectrometry reveals changes in SNAP-25 isoforms in schizophrenia. Schizophrenia Research, 2016, 177, 44-51.	1.1	17
300	Decreased cortical FADD protein is associated with clinical dementia and cognitive decline in an elderly community sample. Molecular Neurodegeneration, 2017, 12, 26.	4.4	17
301	Efficacy of high-frequency repetitive transcranial magnetic stimulation on PANSS factors in schizophrenia with predominant negative symptoms â€“ Results from an exploratory re-analysis. Psychiatry Research, 2018, 263, 22-29.	1.7	17
302	Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial. Contemporary Clinical Trials Communications, 2020, 17, 100537.	0.5	17
303	In-depth profiling of COVID-19 risk factors and preventive measures in healthcare workers. Infection, 2022, 50, 381-394.	2.3	17
304	The effect of different degrees of lockdown and self-identified gender on anxiety, depression and suicidality during the COVID-19 pandemic: Data from the international COMET-G study.. Psychiatry Research, 2022, 315, 114702.	1.7	17
305	Differential response to anodal tDCS and PAS is indicative of impaired focal LTP-like plasticity in schizophrenia. Behavioural Brain Research, 2016, 311, 46-53.	1.2	16
306	Unmet Needs in Schizophrenia. CNS and Neurological Disorders - Drug Targets, 2018, 16, 870-884.	0.8	16

#	Article	IF	Citations
307	Differential memory span â€" abnormal lateralization pattern in schizophrenic patients and their siblings?. International Journal of Psychophysiology, 1999, 34, 303-311.	0.5	15
308	Relation between cerebrospinal fluid, gray matter and white matter changes in families with schizophrenia. Journal of Psychiatric Research, 2006, 40, 646-655.	1.5	15
309	Reduction of gyrification index in the cerebellar vermis in schizophrenia: A post-mortem study. World Journal of Biological Psychiatry, 2011, 12, 99-103.	1.3	15
310	Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatment. World Journal of Biological Psychiatry, 2013, 14, 490-499.	1.3	15
311	Impairments of Motor-Cortex Responses to Unilateral and Bilateral Direct Current Stimulation in Schizophrenia. Frontiers in Psychiatry, 2013, 4, 121.	1.3	15
312	Investigations of motor-cortex cortical plasticity following facilitatory and inhibitory transcranial theta-burst stimulation in schizophrenia: A proof-of-concept study. Journal of Psychiatric Research, 2015, 61, 196-204.	1.5	15
313	Aerobic exercise in severe mental illness: requirements from the perspective of sports medicine. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 643-677.	1.8	15
314	Shape changes in prefrontal, but not parieto-occipital regions: brains of schizophrenic patients come closer to a circle in coronal and sagittal view. Psychiatry Research - Neuroimaging, 2004, 132, 261-271.	0.9	14
315	Functional interactions guiding adaptive processing of behavioral significance. Human Brain Mapping, 2009, 30, 3325-3331.	1.9	14
316	Search for copy number variants in chromosomes 15q11-q13 and 22q11.2 in obsessive compulsive disorder. BMC Medical Genetics, 2010, 11, 100.	2.1	14
317	Common and disease-specific dysfunctions of brain systems underlying attentional and executive control in schizophrenia and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 517-532.	1.8	14
318	Polygenic burden associated to oligodendrocyte precursor cells and radial glia influences the hippocampal volume changes induced by aerobic exercise in schizophrenia patients. Translational Psychiatry, 2019, 9, 284.	2.4	14
319	Serum Insulin and Cognitive Performance in Older Adults: A Longitudinal Study. American Journal of Medicine, 2019, 132, 367-373.	0.6	14
320	Effects of 1ÂmA and 2ÂmA transcranial direct current stimulation on working memory performance in healthy participants. Consciousness and Cognition, 2020, 83, 102959.	0.8	14
321	Association Between Physical Activity and Schizophrenia. JAMA Psychiatry, 2021, 78, 441.	6.0	14
322	Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis. Neuropsychopharmacology, 2021, 46, 1484-1493.	2.8	14
323	Intact hippocampal gray matter in schizophrenia as revealed by automatized image analysis postmortem. Anatomy and Embryology, 2005, 210, 513-517.	1.5	13
324	Tryptophan is a marker of human postmortem brain tissue quality. Journal of Neurochemistry, 2009, 110, 1400-1408.	2.1	13

#	Article	IF	Citations
325	Dopamine transporter genotype influencesN-acetyl-aspartate in the left putamen. World Journal of Biological Psychiatry, 2009, 10, 524-530.	1.3	13
326	S100B and homocysteine in the acute alcohol withdrawal syndrome. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 133-138.	1.8	13
327	A Similar but Distinctive Pattern of Impaired Cortical Excitability in First-Episode Schizophrenia and ADHD. Neuropsychobiology, 2013, 67, 74-83.	0.9	13
328	A common risk variant in CACNA1C supports a sex-dependent effect on longitudinal functioning and functional recovery from episodes of schizophrenia-spectrum but not bipolar disorder. European Neuropsychopharmacology, 2015, 25, 2262-2270.	0.3	13
329	The role of environmental stress and DNA methylation in the longitudinal course of bipolar disorder. International Journal of Bipolar Disorders, 2020, 8, 9.	0.8	13
330	Trait Characteristic of Impaired Visuomotor Integration during Trail-Making Test B Performance in Schizophrenia. Neuropsychobiology, 2003, 48, 59-67.	0.9	12
331	Cognition in hepatitis C patients treated with pegylated interferon. World Journal of Biological Psychiatry, 2009, 10, 819-826.	1.3	12
332	Methyl- and acetyltransferases are stable epigenetic markers postmortem. Cell and Tissue Banking, 2011, 12, 289-297.	0.5	12
333	Molecular Signatures of Psychosocial Stress and Cognition Are Modulated by Chronic Lithium Treatment. Schizophrenia Bulletin, 2016, 42, S22-S33.	2.3	12
334	Cerebrospinal Fluid Pathologies in Schizophrenia-Spectrum Disorderâ€"A Retrospective Chart Review. Schizophrenia Bulletin, 2022, 48, 47-55.	2.3	12
335	SNAP-25 genotype influences NAA/Cho in left hippocampus. Journal of Neural Transmission, 2008, 115, 1513-1518.	1.4	11
336	Serotonergic function, substance craving, and psychopathology in detoxified alcohol-addicted males undergoing tryptophan depletion. Journal of Psychiatric Research, 2010, 44, 1163-1169.	1.5	11
337	Proteomic Similarities Between Heterozygous Reeler Mice and Schizophrenia. Biological Psychiatry, 2013, 74, e5-e10.	0.7	11
338	Pioneering ambient mass spectrometry imaging in psychiatry: Potential for new insights into schizophrenia. Schizophrenia Research, 2016, 177, 67-69.	1.1	11
339	Neurocognitive and neuroanatomical maturation in the clinical high-risk states for psychosis: A pattern recognition study. NeuroImage: Clinical, 2019, 21, 101624.	1.4	11
340	Repetitive transcranial magnetic stimulation (rTMS) for schizophrenia patients treated with clozapine. World Journal of Biological Psychiatry, 2021, 22, 14-26.	1.3	11
341	Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 315-324.	1.8	11
342	Polygenic risk scores across the extended psychosis spectrum. Translational Psychiatry, 2021, 11, 600.	2.4	11

#	Article	IF	Citations
343	Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach. British Journal of Psychiatry, 2022, 220, 219-228.	1.7	11
344	Limitations of current therapies: Why do patients switch therapies?. European Neuropsychopharmacology, 2008, 18, S135-S139.	0.3	10
345	Letter to the Editor: Influence of rTMS on smoking in patients with schizophrenia. Schizophrenia Research, 2018, 192, 481-484.	1.1	10
346	Left prefrontal high-frequency rTMS may improve movement disorder in schizophrenia patients with predominant negative symptoms â€“ A secondary analysis of a sham-controlled, randomized multicenter trial. Schizophrenia Research, 2019, 204, 445-447.	1.1	10
347	Multifactorial barriers in the implementation of schizophrenia and psychosocial therapies guidelines: A quantitative study across different professions. Schizophrenia Research, 2021, 228, 425-434.	1.1	10
348	The progression of disorder-specific brain pattern expression in schizophrenia over 9 years. NPJ Schizophrenia, 2021, 7, 32.	2.0	10
349	Improvement in daily functioning after aerobic exercise training in schizophrenia is sustained after exercise cessation. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1201-1203.	1.8	10
350	HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders. Scientific Reports, 2021, 11, 17823.	1.6	10
351	The clinical relevance of formal thought disorder in the early stages of psychosis: results from the PRONIA study. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 403-413.	1.8	10
352	Exercise as a model to identify microRNAs linked to human cognition: a role for microRNA-409 and microRNA-501. Translational Psychiatry, 2021, 11, 514.	2.4	10
353	Cognitive and functional deficits are associated with white matter abnormalities in two independent cohorts of patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 957-969.	1.8	10
354	Schizophrenia Spectrum Disorders: A Review. , 2001, , 311-405.		9
355	Differential working memory performance as support for the Kraepelinian dichotomy between schizophrenia and bipolar disorder? An experimental neuropsychological study using circuit-specific working memory tasks. World Journal of Biological Psychiatry, 2013, 14, 258-267.	1.3	9
356	Psychiatristsâ€™ self-stigma, the DGPPN guideline for psychosocial interventions, and contemporary treatment strategies. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 171-172.	1.8	9
357	Effects of haloperidol and clozapine on synapse-related gene expression in specific brain regions of male rats. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 555-563.	1.8	9
358	The influence of religious activity and polygenic schizophrenia risk on religious delusions in schizophrenia. Schizophrenia Research, 2019, 210, 255-261.	1.1	9
359	Association between altered hippocampal oligodendrocyte number and neuronal circuit structures in schizophrenia: a postmortem analysis. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 413-424.	1.8	9
360	Clinical and Neurodevelopmental Aspects of Brain Pathology in Schizophrenia. , 1991, , 93-120.		9

#	Article	IF	Citations
361	Abnormalities of prefrontal cortex SNARE complex proteins in bipolar disorder. Bipolar Disorders, 2002, 4, 50-50.	1.1	8
362	Promoting stigma coping and empowerment in patients with schizophrenia and depression: results of a cluster-RCT. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 501-511.	1.8	8
363	An overview of the human brain myelin proteome and differences associated with schizophrenia. World Journal of Biological Psychiatry, 2021, 22, 271-287.	1.3	8
364	Nonpharmacological treatment of dyscognition in schizophrenia: effects â€¨of aerobic exercise. Dialogues in Clinical Neuroscience, 2019, 21, 261-269.	1.8	8
365	Medication Adherence in a Cross-Diagnostic Sample of Patients From the Affective-to-Psychotic Spectrum: Results From the PsyCourse Study. Frontiers in Psychiatry, 2021, 12, 713060.	1.3	8
366	A roadmap to disentangle the molecular etiology of schizophrenia. European Psychiatry, 2008, 23, 224-232.	0.1	7
367	A desperate search for biomarkers in schizophrenia. What is going wrong?. World Psychiatry, 2011, 10, 38-39.	4.8	7
368	Pattern and volume of the anterior cingulate cortex in chronic posttraumatic stress disorder (PTSD). European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 585-592.	1.8	7
369	The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) influences age at onset of obsessiveâ€“compulsive disorder. International Journal of Neuropsychopharmacology, 2013, 16, 1951-1958.	1.0	7
370	Neuroscience-based nomenclature (jNbN) to replace traditional terminology of psychotropic medications. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 385-386.	1.8	7
371	Psychoeducational and Cognitive Behavioral Treatment Programs: Implementation and Evaluation From 1995 to 2015 in Kraepelinâ€™s Former Hospital. Schizophrenia Bulletin, 2016, 42, S81-S89.	2.3	7
372	Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. BMC Psychiatry, 2016, 16, 153.	1.1	7
373	Aerobic exercise in mental disorders: from basic mechanisms to treatment recommendations. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 483-484.	1.8	7
374	Premature mortality, causes of death, and mental disorders. Lancet, The, 2019, 394, 1784-1786.	6.3	7
375	The Influence of Continuous Exercising on Chronotropic Incompetence in Multi-Episode Schizophrenia. Frontiers in Psychiatry, 2019, 10, 90.	1.3	7
376	Efficient region-based test strategy uncovers genetic risk factors for functional outcome in bipolar disorder. European Neuropsychopharmacology, 2019, 29, 156-170.	0.3	7
377	Selfâ€esteem fully mediates positive life events and depressive symptoms in a sample of 173 patients with affective disorders. Psychology and Psychotherapy: Theory, Research and Practice, 2020, 93, 21-35.	1.3	7
378	Role of psychiatric hospitals during a pandemic: introducing the Munich Psychiatric COVID-19 Pandemic Contingency Plan. BJPsych Open, 2021, 7, e41.	0.3	7

#	Article	IF	Citations
379	A genome-wide association study of the longitudinal course of executive functions. Translational Psychiatry, 2021, 11, 386.	2.4	7
380	Acquisition and Use of â€˜Priorsâ€™ in Autism: Typical in Deciding Where to Look, Atypical in Deciding What Is There. Journal of Autism and Developmental Disorders, 2021, 51, 3744-3758.	1.7	7
381	A Primeval Mechanism of Tolerance to Desiccation Based on Glycolic Acid Saves Neurons in Mammals from Ischemia by Reducing Intracellular Calciumâ€Mediated Excitotoxicity. Advanced Science, 2022, 9, e2103265.	5.6	7
382	Altered cholesterol metabolism in APP695-transfected neuroblastoma cells. Brain Research, 2007, 1152, 209-214.	1.1	6
383	The impact of endurance training and table soccer on brain metabolites in schizophrenia. Brain Imaging and Behavior, 2020, 14, 515-526.	1.1	6
384	Genetic risk for psychiatric illness is associated with the number of hospitalizations of bipolar disorder patients. Journal of Affective Disorders, 2022, 296, 532-540.	2.0	6
385	Chronic vs non-chronic depression in psychiatric inpatient care - Data from a large naturalistic multicenter trial. Journal of Affective Disorders, 2022, 299, 73-84.	2.0	6
386	Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages. JAMA Psychiatry, 2022, 79, 677.	6.0	6
387	Automated gray level index measurements reveal only minor cytoarchitectonic changes of Brodmann area 9 in schizophrenia. Psychiatry Research - Neuroimaging, 2008, 163, 183-192.	0.9	5
388	The LARK/RBM4a protein is highly expressed in cerebellum as compared to cerebrum. Neuroscience Letters, 2008, 444, 11-15.	1.0	5
389	Psychopathology: genetics and the stress-vulnerability hypothesis. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 181-182.	1.8	5
390	Polygenic analysis suggests the involvement of calcium signaling in executive function in schizophrenia patients. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 425-431.	1.8	5
391	The Generalized Adaptation Account of Autism. Frontiers in Neuroscience, 2020, 14, 534218.	1.4	5
392	A machine learning approach to risk assessment for alcohol withdrawal syndrome. European Neuropsychopharmacology, 2020, 35, 61-70.	0.3	5
393	The safety of agomelatine in standard medical practice in depressed patients: A 26â€week international multicentre cohort study. Human Psychopharmacology, 2021, 36, 1-11.	0.7	5
394	Linking proteomic alterations in schizophrenia hippocampus to NMDAr hypofunction in human neurons and oligodendrocytes. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1579-1586.	1.8	5
395	Effects of Marathon Running on Cognition and Retinal Vascularization: A Longitudinal Observational Study. Medicine and Science in Sports and Exercise, 2021, 53, 2207-2214.	0.2	5
396	Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. World Journal of Biological Psychiatry, 0, , 1-8.	1.3	5

#	Article	IF	Citations
397	Basic Symptoms Are Associated With Age in Patients With a Clinical High-Risk State for Psychosis: Results From the PRONIA Study. Frontiers in Psychiatry, 2020, 11, 552175.	1.3	5
398	Expression of Lineage Transcription Factors Identifies Differences in Transition States of Induced Human Oligodendrocyte Differentiation. Cells, 2022, 11, 241.	1.8	5
399	Cerebrospinal fluid abnormalities in first- and multi-episode schizophrenia-spectrum disorders: impact of clinical and demographical variables. Translational Psychiatry, 2021, 11, 621.	2.4	5
400	Changes and Challenges in Inpatient Mental Health Care During the First Two High Incidence Phases of the COVID-19 Pandemic in Germany â€“ Results From the COVID Î¨ Psychiatry Survey. Frontiers in Psychiatry, 2022, 13, 855040.	1.3	5
401	Projecting the sulcal pattern of human brains onto a 2D plane â€” a new approach using potential theory and MRI. Psychiatry Research - Neuroimaging, 1998, 83, 75-84.	0.9	4
402	Understanding mental disorders from neuronal networks to glial cells and proteomics. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 441-442.	1.8	4
403	Predictors of symptomatic remission in first-episode psychosis outpatients treated with quetiapine: A naturalistic study. International Journal of Psychiatry in Clinical Practice, 2013, 17, 148-153.	1.2	4
404	Nicotineâ€“dopamine-transporter interactions during reward-based decision making. European Neuropsychopharmacology, 2016, 26, 938-947.	0.3	4
405	Aerobic exercise in major psychiatric disorders: promises and challenges. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 93-94.	1.8	4
406	Trends in Schizophrenia Diagnosis and Treatment. , 2019, , 603-619.		4
407	Predicting instructed simulation and dissimulation when screening for depressive symptoms. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 153-168.	1.8	4
408	Brain Network Simulations Indicate Effects of Neuregulin-1 Genotype on Excitation-Inhibition Balance in Cortical Dynamics. Cerebral Cortex, 2021, 31, 2013-2025.	1.6	4
409	Differential gene regulation in the anterior cingulate cortex and superior temporal cortex in schizophrenia: A molecular network approach. Schizophrenia Research, 2021, 232, 1-10.	1.1	4
410	A Novel Mutation of the Arylsulfatase A Gene in Late-Onset Metachromatic Leukodystrophy. Journal of Clinical Psychiatry, 2009, 70, 1724-1725.	1.1	4
411	Association between aerobic fitness and the functional connectome in patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1253-1272.	1.8	4
412	Large-Scale Inverse and Forward Modeling of Adaptive Resonance in the Tinnitus Decompensation. , 2006, 2006, 2585-8.		3
413	Biomarkers and neurobiology of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 363-364.	1.8	3
414	Therapeutic targets in major psychiatric disorders revisited. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 619-620.	1.8	3

#	Article	IF	Citations
415	The neuropathology of schizophrenia: new insights from postmortem studies. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 269-270.	1.8	3
416	Negative symptoms and therapy strategies in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 541-542.	1.8	3
417	Effects of Three Months of Aerobic Endurance Training on Motor Cortical Excitability in Schizophrenia Patients and Healthy Subjects. Neuropsychobiology, 2020, 79, 100-107.	0.9	3
418	Was King Ludwig II of Bavaria misdiagnosed by Gudden and his colleagues?. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 799-807.	1.8	3
419	The revised DGPPN and APA schizophrenia guidelines: Guideline quality and recommendations for long-term antipsychotic treatment. Schizophrenia Research, 2021, 229, 137-139.	1.1	3
420	The Interplay Between Postsynaptic Striatal D2/3 Receptor Availability, Adversity Exposure and Odd Beliefs: A [11C]-Raclopride PET Study. Schizophrenia Bulletin, 2021, 47, 1495-1508.	2.3	3
421	Decreased Serum Brain-Derived Neurotrophic Factor Concentrations 72 Hours Following Marathon Running. Frontiers in Physiology, 2021, 12, 668454.	1.3	3
422	The Neuropathology of Schizophrenia: Central Role for the Hippocampus?. , 2010, , 149-165.		3
423	Estudos transcriptÃ´micos no contexto da conectividade perturbada em esquizofrenia. Revista De Psiquiatria Clinica, 2013, 40, 10-15.	0.6	3
424	Lower Emotion Regulation Competencies Mediate the Association between Impulsivity and Craving during Alcohol Withdrawal Treatment. Substance Use and Misuse, 2022, 57, 649-655.	0.7	3
425	The role of migration in mental healthcare: treatment satisfaction and utilization. BMC Psychiatry, 2022, 22, 116.	1.1	3
426	Anodal transcranial direct current stimulation sustainably increases <scp>EEG</scp> alpha activity in patients with schizophrenia. Neuropsychopharmacology Reports, 2022, 42, 323-332.	1.1	3
427	Ventajas y desventajas del tratamiento de combinaciÃ³n con antipsicÃ³ticos. ReuniÃ³n ECNP Consensus, marzo de 2008, Niza. Psiquiatria Biologica, 2011, 18, 55-67.	0.0	2
428	Differential diagnosis of major depression and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 83-84.	1.8	2
429	The new risk variant CACNA1C and brain circuits in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 91-92.	1.8	2
430	Comorbidity, stigma and emotional perception in psychiatric disorders. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 1-2.	1.8	2
431	Historical aspects of Mozartâ€™s mental health and diagnostic insights of ADHD and personality disorders. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 363-365.	1.8	2
432	Suicide ideation, stability of symptoms and effects of aerobic exercise in major depression. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 555-556.	1.8	2

#	Article	IF	Citations
433	Erythropoietin as an Innovative Add-on Therapy for Depression. Biological Psychiatry, 2015, 78, 222-223.	0.7	2
434	Schizophrenia spectrum and related neuropathology. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 85-86.	1.8	2
435	Classification and neurobiological concepts of mania, bipolar disorder and major depression. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 271-272.	1.8	2
436	News from the graveyard: Neuropathological research on schizophrenia is alive and productive. Schizophrenia Research, 2016, 177, 1-2.	1.1	2
437	Perspectives of neurobiological research in schizophrenia. Neurology Psychiatry and Brain Research, 2016, 22, 63-68.	2.0	2
438	Special Supplement Introduction: The Fourth Kraepelin Symposiumâ€"Cognitive Dysfunction in Schizophrenia: Origins and Innovative Treatment. Schizophrenia Bulletin, 2016, 42, S1-S3.	2.3	2
439	Morphological and functional alterations in patients with schizophrenia spectrum disorders. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 1-2.	1.8	2
440	Schizophrene Psychosen. , 2017, , 1583-1674.		2
441	Effects of exercise-based interventions in severe mental illness: a feasibility study. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 621-622.	1.8	2
442	Changes in antidepressant therapy should be considered early in patients with inadequate response to a first-line agent. Australian and New Zealand Journal of Psychiatry, 2020, 55, 000486742096891.	1.3	2
443	Effects of Smoking Status on Remission and Metabolic and Cognitive Outcomes in Schizophrenia Patients Treated with Clozapine. Pharmacopsychiatry, 2020, 53, 273-283.	1.7	2
444	Impact of the metabolic syndrome on severe mental disorders. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 499-500.	1.8	2
445	Effect of aerobic exercise on cortical thickness in patients with schizophreniaâ€"A dataset. Data in Brief, 2020, 30, 105517.	0.5	2
446	Effects of high-frequency prefrontal rTMS on heart frequency rates and blood pressure in schizophrenia. Journal of Psychiatric Research, 2021, 140, 243-249.	1.5	2
447	Novel Gyrification Networks Reveal Links with Psychiatric Risk Factors in Early Illness. Cerebral Cortex, 2021, , .	1.6	2
448	Somatische Therapieverfahren. , 2016, , 77-105.		2
449	Investigating the phenotypic and genetic associations between personality traits and suicidal behavior across major mental health diagnoses. European Archives of Psychiatry and Clinical Neuroscience, 2022, , 1.	1.8	2
450	Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health. Frontiers in Psychiatry, 2022, 13, 815718.	1.3	2

#	Article	IF	Citations
451	Stability over time of scores on psychiatric rating scales, questionnaires and cognitive tests in healthy controls. BJPsych Open, 2022, 8, e55.	0.3	2
452	A novel longitudinal clustering approach to psychopathology across diagnostic entities in the hospital-based PsyCourse study. Schizophrenia Research, 2022, 244, 29-38.	1.1	2
453	Schizophrenia Spectrum Disorders: A Review. , 2003, , 317-411.		1
454	Schizophrenia: from risk genes to outcome and comorbidity. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 547-548.	1.8	1
455	Impact of lifestyle in severe psychiatric disorders and brain morphology. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 449-450.	1.8	1
456	Risk genes, metabolic syndrome and eye tracking deficits in psychiatric diseases. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 177-179.	1.8	1
457	Schizophrenia: brain morphology and treatment aspects. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 1-2.	1.8	1
458	Family load impacts orbitofrontal volume in first-episode schizophrenia. Psychiatry Research - Neuroimaging, 2015, 232, 130-133.	0.9	1
459	Pathways to personalized treatment strategies for depressive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 1-3.	1.8	1
460	Genetic and environmental risk factors in neurodevelopmental disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 445-447.	1.8	1
461	Stepping up: the just released new impact factor 2015. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 475-476.	1.8	1
462	Commentary on â€œSystems Neuroscience of Psychosis (SyNoPsis): Mapping Schizophrenia Symptoms onto Brain Systemsâ€• Neuropsychobiology, 2017, 75, 122-123.	0.9	1
463	Reply to: Sample Size, Model Robustness, and Classification Accuracy in Diagnostic Multivariate Neuroimaging Analyses. Biological Psychiatry, 2018, 84, e83-e84.	0.7	1
464	Effectiveness and cost-effectiveness of an integrated care program for schizophrenia: an analysis of routine data. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 611-619.	1.8	1
465	Impaired recovery in affective disorders and schizophrenia: sharing a common pathophysiology?. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 739-740.	1.8	1
466	F182. SYMPTOM-RELATED STRUCTURAL BRAIN PATTERN IN PATIENTS WITH SCHIZOPHRENIA-A PARTIAL LEAST SQUARE ANALYSIS. Schizophrenia Bulletin, 2018, 44, S292-S292.	2.3	1
467	Psychiatry and psychiatrists: Fourteen core statements. European Psychiatry, 2018, 52, 136-138.	0.1	1
468	Personality Traits in Marathon Runners and Sedentary Controls With MMPI-2-RF. Frontiers in Psychology, 2020, 11, 886.	1.1	1

#	Article	IF	Citations
469	Schizophrene Psychosen. , 2016, , 1-92.		1
470	Ã„tiopathogenetische BeitrÃge der Bildgebungsforschung in der Psychiatrie. , 2017, , 215-243.		1
471	Massive, Previously Undetected Cancer Metastasis Revealed by Application of a Depot Antipsychotic. Journal of Clinical Psychiatry, 2014, 75, e705-e706.	1.1	1
472	Obituary â€“ Prof. Dr. Hanns Hippius (1925 â€“ 2021). International Journal of Neuropsychopharmacology, 2021, 24, 856-857.	1.0	1
473	Interplay between the genetics of personality traits, severe psychiatric disorders and COVID-19 host genetics in the susceptibility to SARS-CoV-2 infection. BJPsych Open, 2021, 7, e188.	0.3	1
474	Macroanatomical Findings in Postmortem Brain Tissue from Schizophrenic Patients. Neurobiological Foundation of Aberrant Behaviors, 2002, , 139-150.	0.2	1
475	Using combined environmentalâ€“clinical classification models to predict role functioning outcome in clinical high-risk states for psychosis and recent-onset depression. British Journal of Psychiatry, 2022, 220, 229-245.	1.7	1
476	Pattern of predictive features of continued cannabis use in patients with recent-onset psychosis and clinical high-risk for psychosis. NPJ Schizophrenia, 2022, 8, 19.	2.0	1
477	Failed regeneration and inflammation in schizophrenia: two sides of the same coin?. Journal of Neural Transmission, 2022, , 1.	1.4	1
478	Exercise addiction measured at a naturalistic marathon-event â€“ associations of the EAI with the general level of functioning, affect and performance parameters. International Journal of Sport and Exercise Psychology, 2023, 21, 1041-1053.	1.1	1
479	The cytoarchitecture of the superior temporal gyrus in bipolar disorder using GLI-methodology. Bipolar Disorders, 2002, 4, 49-49.	1.1	0
480	Sleep, hypothalamus, and stigma. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 563-564.	1.8	0
481	The Hypoxic Rat Model for Obstetric Complications in Schizophrenia. Neuromethods, 2011, , 93-111.	0.2	0
482	Treatment of first-episode schizophrenia: pharmacological and neurobiological aspects. Drug Discovery Today: Therapeutic Strategies, 2011, 8, 31-35.	0.5	0
483	The new impact factor in 2011 of EAPCN. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 457-458.	1.8	0
484	On our own behalf: a new editorial board and focus of EAPCN. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 545-546.	1.8	0
485	Post-mortem findings in mood disorders, nightmares and therapeutic approaches of psychiatric diseases. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 635-636.	1.8	0
486	Selected issues of the DGPPN Congress in 2011. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 49-50.	1.8	0

#	Article	IF	Citations
487	From pathophysiological aspects towards unravelling the neurobiological background of cognitive deficits. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 275-276.	1.8	0
488	The glutamate system as a therapeutic target and impact of genes on suicidality. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 365-366.	1.8	0
489	Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimerâ€™s disease. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 271-272.	1.8	0
490	Selected topics of the DGPPN Congress 2012. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 121-122.	1.8	0
491	Brain imaging to be on track for improving diagnosis and pathophysiological insights in neuropsychiatric diseases. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 537-538.	1.8	0
492	Selected issues of the DGPPN Congress in 2013. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 1-2.	1.8	0
493	New aspects of cognition domains and psychopathological measures in psychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 647-649.	1.8	0
494	Connectivity and cognition in neuropsychiatric disorders with special emphasis on Alzheimerâ€™s disease and Chorea Huntington. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 465-466.	1.8	0
495	Reward, memory and prediction of treatment response in affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 185-186.	1.8	0
496	Unravelling basic mechanisms in addiction and neuropsychiatric disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 633-635.	1.8	0
497	DGPPN guideline on anxiety disorders and cognitive dysfunction in the elderly or patients with multiple sclerosis. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 361-362.	1.8	0
498	Aerobic exercise for people with schizophrenic psychosis. , 2016, , 66-78.		0
499	Neurobiological background of borderline personality disorder, PTSD and ADHD. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 289-290.	1.8	0
500	On the search of new treatment strategies in patients with affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 709-710.	1.8	0
501	174.4 Using Machine Learning to Predict Outcomes in Psychosis. Schizophrenia Bulletin, 2017, 43, S88-S88.	2.3	0
502	170. Targeting Dysplasticity in Schizophrenia via Aerobic Exercise: Understanding the Mechanisms. Schizophrenia Bulletin, 2017, 43, S86-S86.	2.3	0
503	11.3 CLINICAL AND NEUROBIOLOGICAL EFFECTS OF A CONTINUOUS AEROBIC ENDURANCE TRAINING IN MULTI-EPISODE SCHIZOPHRENIA PATIENTS. Schizophrenia Bulletin, 2018, 44, S17-S18.	2.3	0
504	S177. FRONTAL CORTICAL PLASTICITY IN SCHIZOPHRENIA PATIENTS EXAMINED BY LTP-INDUCING ANODAL TDCS AND REPETITIVE EEG. Schizophrenia Bulletin, 2018, 44, S393-S394.	2.3	0

#	Article	IF	Citations
505	S47. ADD-ON SPIRONOLACTONE FOR THE TREATMENT OF SCHIZOPHRENIA (SPIRO TREAT). Schizophrenia Bulletin, 2018, 44, S342-S342.	2.3	0
506	F107. CSF ABNORMALITIES IN SCHIZOPHRENIA AND DEPRESSION: PRELIMINARY RESULTS FROM A LARGE SCALE COHORT. Schizophrenia Bulletin, 2018, 44, S261-S261.	2.3	0
507	S79. ENHANCING WORKING MEMORY IN SCHIZOPHRENIA USING 1MA AND 2MA TRANSCRANIAL DIRECT STIMULATION TO THE LEFT DORSOLATERAL PREFRONTAL CORTEX. Schizophrenia Bulletin, 2018, 44, S355-S355.	2.3	0
508	S49. EFFICACY OF HIGH-FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION ON PANSS FACTORS IN SCHIZOPHRENIA WITH PREDOMINANT NEGATIVE SYMPTOMS â€“ RESULTS FROM AN EXPLORATORY RE-ANALYSIS. Schizophrenia Bulletin, 2018, 44, S343-S343.	2.3	0
509	F185. BRAIN STRUCTURAL PATTERNS DIFFERENTIATE EARLY- AND LATE-ONSET CANNABIS USE IN PSYCHOTIC PATIENTS: PRELIMINARY RESULTS FROM THE PRONIA STUDY. Schizophrenia Bulletin, 2018, 44, S293-S293.	2.3	0
510	T102. AN INVESTIGATION OF SCHIZOPHRENIA-BIPOLAR SUBGROUPS WITH GENETIC AND PROGNOSTIC VALIDATION. Schizophrenia Bulletin, 2018, 44, S155-S155.	2.3	0
511	Psychotherapeutische und psychosoziale Interventionen (Modul 4b). , 2019, , 139-180.		0
512	Cover Image, Volume 180B, Number 2, March 2019. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, i.	1.1	0
513	Modeling Obstetric Complications in Schizophrenia. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1070-1071.	1.1	0
514	Affected neural networks as basis of disturbed motor function in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 279-280.	1.8	0
515	Kausale Therapie der Schizophrenie mÃ¶glich?. , 2003, , 15-16.		0
516	Brain morphological abnormalities in first-degree relatives of schizophrenic patients. , 2004, , 254-266.		0
517	Ã„tiopathogenetische BeitrÃge der Bildgebungsforschung in der Psychiatrie. , 2016, , 1-28.		0
518	Sonstige Therapien. , 2016, , 177-194.		0
519	Ã„tiopathogenetische BeitrÃge der Bildgebungsforschung in der Psychiatrie. , 2017, , 1-29.		0
520	Versorgungskoordination (Modul 5). , 2019, , 271-299.		0
521	Allgemeine Grundlagen (Modul 1). , 2019, , 1-12.		0
522	Behandlung unter besonderen Bedingungen (Modul 4c). , 2019, , 181-254.		0

#	Article	IF	Citations
523	Pharmakotherapie und andere somatische Behandlungsverfahren (Modul 4a). , 2019, , 51-137.		0
524	Klassifikation, Diagnostik und Differenzialdiagnostik (Modul 2). , 2019, , 13-36.		0
525	Neuro-psychopharmacotherapy and the Differential Diagnostic Approaches in Europe. , 2020, , 1-30.		0
526	Psychiatry: Peter Falkai. Journal of Neural Transmission, 2022, , 1.	1.4	0
527	The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post hoc analysis of three randomized, placebo-controlled trials. CNS Spectrums, 2021, , 1-8.	0.7	0
528	Large-Scale Inverse and Forward Modeling of Adaptive Resonance in the Tinnitus Decompensation. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0